Darifenacin: another antimuscarinic for overactive bladder

Area of Science:

• Pharmacology
• Urology

Background:

• Overactive bladder (OAB) affects millions globally, necessitating effective treatments.
• Anticholinergic medications are a cornerstone of OAB management.
• Darifenacin, approved in 2004, is a novel anticholinergic agent targeting OAB.

Purpose of the Study:

• To review the efficacy and safety of darifenacin for overactive bladder.
• To assess the preclinical and clinical data supporting darifenacin's use.
• To compare darifenacin's profile with existing anticholinergic therapies.

Main Methods:

• Comprehensive literature search of MEDLINE/PUBMED and conference proceedings (1986-2004).
• Inclusion of all studies on darifenacin (in vitro, animal, and human).
• Review of preclinical data on receptor antagonism and clinical trial results.

Main Results:

• Preclinical studies indicated darifenacin as a M1, M3, M5 muscarinic receptor antagonist, suggesting potential "uroselectivity."
• Darifenacin (7.5-15 mg daily) significantly reduced OAB symptoms (micturitions, incontinence, urgency) compared to placebo.
• Common adverse effects included dry mouth and constipation; "uroselectivity" was not confirmed in clinical trials.

Conclusions:

• Darifenacin demonstrates efficacy in reducing OAB symptoms but its purported "uroselectivity" remains unproven in clinical settings.
• Lack of comparative trials against existing anticholinergics limits definitive assessment of its therapeutic advancement.
• Current evidence suggests darifenacin may not represent a significant improvement over established anticholinergic treatments for OAB.